As scientists and clinicians, we have dedicated our careers to an integrated approach to responding to disease and conditions driving adverse human health. With our understanding of the Microbiome, we have developed patented technology to disrupt the disease cascade of the myriad of diseases and health conditions strongly associated with the Human Microbiome.
Scaled Microbiomics has discovered solutions that can be rapidly and cost-effectively developed and deployed to address human health needs- providing diagnostics, prophylactics, and treatments to combat targeted conditions with our patented platform technology.
To protect and change society by leading the way in disease interception based on modulating microbiome signaling pathways and providing innovative therapeutics across a broad spectrum of disease states.
Intercepting microbiome-driven disease and supporting wellness with targeted, passive immunotherapeutics that modulate microbiome-host signaling pathways through rational systems biology-based drug design.
As scientists and clinicians, we have dedicated our careers to an integrated approach to responding to disease and conditions driving adverse human health. With our understanding of the Microbiome, we have developed patented technology to disrupt the disease cascade of the myriad of diseases and health conditions strongly associated with the Human Microbiome.
Scaled Microbiomics has discovered solutions that can be rapidly and cost-effectively developed and deployed to address human health needs- providing diagnostics, prophylactics, and treatments to combat targeted conditions with our patented platform technology.
To protect and change society by leading the way in disease interception based on modulating microbiome signaling pathways and providing innovative therapeutics across a broad spectrum of disease states.
Intercepting microbiome-driven disease and supporting wellness with targeted, passive immunotherapeutics that modulate microbiome-host signaling pathways through rational systems biology-based drug design.
Our expertise lies in driving an antibody approach to Subtractive Microbiomic Therapies.
Our innovative approach combines an understood regulatory pathway (antibodies) with exciting new understanding of the microbiome manipulation to allow SMB to rapidly develop diagnostic and therapeutic interventions as an order of magnitude less time and cost.
We currently collaborate with academic experts in certain diseases and have developed a platform that can be efficiently directed at whatever target pathobiont is associated with microbiome dysbiosis and disease cascades.
Our expertise lies in driving an antibody approach to Subtractive Microbiomic Therapies.
Our innovative approach combines an understood regulatory pathway (antibodies) with exciting new understanding of the microbiome manipulation to allow SMB to rapidly develop diagnostic and therapeutic interventions as an order of magnitude less time and cost.
We currently collaborate with academic experts in certain diseases and have developed a platform that can be efficiently directed at whatever target pathobiont is associated with microbiome dysbiosis and disease cascades.
SMB partners in the diagnostic and therapeutic sector, but can also offer high quality, low cost incredients to the supplement market. Our base material is GRAS (Generally Regarded as Safe) and by definition has an outstanding safety profile.
SMB partners in the diagnostic and therapeutic sector, but can also offer high quality, low cost incredients to the supplement market. Our base material is GRAS (Generally Regarded as Safe) and by definition has an outstanding safety profile.
Board Member
Board Member
VP of Business Development
Chief Scientific Officer
Chief Scientific Officer in Lab
Avian Agriculturalist
Interim CEO
Board Member
VP of Business Development
Chief Scientific Officer
Chief Scientific Officer in Lab
Avian Agriculturalist